Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Short Interest Update

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw a large increase in short interest in December. As of December 31st, there was short interest totaling 40,313 shares, an increase of 29.1% from the December 15th total of 31,224 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 25,648 shares, the short-interest ratio is presently 1.6 days. Based on an average daily volume of 25,648 shares, the short-interest ratio is presently 1.6 days. Approximately 0.1% of the company’s stock are sold short.

Hedge Funds Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. acquired a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Analyst Upgrades and Downgrades

NBTX has been the topic of several analyst reports. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Wall Street Zen raised Nanobiotix to a “hold” rating in a report on Saturday, October 25th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $11.00.

Nanobiotix Trading Down 1.1%

Shares of Nanobiotix stock opened at $20.76 on Tuesday. The company’s fifty day simple moving average is $21.55 and its 200-day simple moving average is $15.90. Nanobiotix has a 1-year low of $2.95 and a 1-year high of $30.35.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.